期刊
ONCOIMMUNOLOGY
卷 1, 期 6, 页码 997-999出版社
LANDES BIOSCIENCE
DOI: 10.4161/onci.19865
关键词
BRAF; BRAF mutation; CTLA-4; immunotherapy; immune response; melanoma; pathology; tumor infiltrating lymphocytes; targeted therapy
Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic benefits. This commentary reviews immune responses induced by BRAF inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
